

Ying Su

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8279730/publications.pdf>

Version: 2024-02-01

25
papers

785
citations

516710

16
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1156
citing authors

#	ARTICLE	IF	CITATIONS
1	Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy. <i>Molecular Cell</i> , 2017, 66, 141-153.e6.	9.7	215
2	NSAID Sulindac and Its Analog Bind RXR α and Inhibit RXR α -Dependent AKT Signaling. <i>Cancer Cell</i> , 2010, 17, 560-573.	16.8	112
3	Oncogenic potential of truncated RXR α during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling. <i>Nature Communications</i> , 2019, 10, 1463.	12.8	45
4	Sulindac-Derived RXR α Modulators Inhibit Cancer Cell Growth by Binding to a Novel Site. <i>Chemistry and Biology</i> , 2014, 21, 596-607.	6.0	39
5	Regulation of the nongenomic actions of retinoid X receptor- α by targeting the coregulator-binding sites. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 102-112.	6.1	36
6	Targeting Truncated Retinoid X Receptor- α by CF31 Induces TNF- α -Dependent Apoptosis. <i>Cancer Research</i> , 2013, 73, 307-318.	0.9	33
7	Identification of a New RXR α Antagonist Targeting the Coregulator-Binding Site. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 736-741.	2.8	29
8	Nitrostyrene Derivatives Act as RXR α Ligands to Inhibit TNF α Activation of NF- κ B. <i>Cancer Research</i> , 2015, 75, 2049-2060.	0.9	29
9	Celastrol binds to its target protein <i>via</i> specific noncovalent interactions and reversible covalent bonds. <i>Chemical Communications</i> , 2018, 54, 12871-12874.	4.1	26
10	Targeting truncated RXR α for cancer therapy. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 49-59.	2.0	25
11	Ultra-High-Throughput Screening of Natural Product Extracts to Identify Proapoptotic Inhibitors of Bcl-2 Family Proteins. <i>Journal of Biomolecular Screening</i> , 2014, 19, 1201-1211.	2.6	24
12	SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway. <i>European Journal of Medicinal Chemistry</i> , 2019, 177, 171-187.	5.5	24
13	BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 886-899.	4.1	20
14	Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1278-1283.	2.8	19
15	Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 663-675.	2.1	18
16	Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXR α . <i>Nature Communications</i> , 2017, 8, 16066.	12.8	17
17	Design, synthesis and biological evaluation of tetrazole-containing RXR α ligands as anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 562-575.	5.5	15
18	Synthesis and SAR study of modulators inhibiting tRXR α -dependent AKT activation. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 632-648.	5.5	14

#	ARTICLE	IF	CITATIONS
19	Discovery of atorvastatin as a tetramer stabilizer of nuclear receptor RXR α through structure-based virtual screening. <i>Bioorganic Chemistry</i> , 2019, 85, 413-419.	4.1	11
20	Virtual screening and experimental validation identify novel modulators of nuclear receptor RXR α from Drugbank database. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1055-1061.	2.2	10
21	Optimization of novel oxidative DIMs as Nur77 modulators of the Nur77-Bcl-2 apoptotic pathway. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113020.	5.5	8
22	Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1000-1004.	2.2	6
23	Binding characterization, synthesis and biological evaluation of RXR α antagonists targeting the coactivator binding site. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3846-3849.	2.2	6
24	Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPAR α with potential anti-diabetic efficacy. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113542.	5.5	4
25	Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation. <i>FASEB Journal</i> , 2012, 26, 766.12.	0.5	0